Two different things: approved vs. compounded
FDA approval and pharmacy compounding are two separate pathways, and conflating them is the most common source of confusion in the peptide world. An FDA-approved medicine has gone through clinical trials and a formal review of safety, effectiveness, manufacturing, and labeling for a specific use. A compounded medication has not.
Compounding is the practice of a licensed pharmacy preparing a medication tailored to an individual patient — for example, when a commercial product isn't available in the needed form or a patient can't tolerate an ingredient. Compounded preparations are legal and longstanding, but they are not FDA-approved and are not reviewed by the FDA for safety or effectiveness.
503A vs. 503B pharmacies
Federal law recognizes two kinds of compounding. A 503A pharmacy compounds patient-specific prescriptions — one preparation for one named patient with a valid prescription. A 503B 'outsourcing facility' can compound in larger batches under stricter, FDA-registered manufacturing standards (current good manufacturing practice), often for clinics and hospitals.
Neither 503A nor 503B output is 'FDA-approved,' but the two operate under different quality frameworks. Knowing which kind of pharmacy prepared a medication is a fair question to ask, and a legitimate provider will be able to answer it.
Why the regulatory category matters
Whether a given substance can be compounded at all depends on federal categories. Some bulk substances are explicitly permitted; others are under review; and some are not eligible absent further FDA rulemaking. A peptide's category determines whether a pharmacy may legally compound it — but it says nothing about how well that peptide works.
In other words: a category that permits compounding is a regulatory permission, not a clinical endorsement. It is a different framework with a different bar than approval, and we keep that distinction explicit on every profile.
How Clyne talks about it
Wherever a peptide is compounded, we label it as compounded — on the storefront, in the catalog, and in this concierge. We never describe a compounded peptide as FDA-approved, and we don't imply that eligibility for compounding means a peptide has been proven safe or effective.
If a peptide is an FDA-approved active (the molecule itself has been approved), we'll say that too, and explain what it was approved to do. The honest version is usually more nuanced than marketing copy — and that's the point.